Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Insulin, 20 units Clear all
Completed Phase 2 Interventional Results available

Intranasal Insulin in Parkinson's Disease

NCT04251585
View directory record Official record
Conditions
Parkinson Disease
Interventions
Regular Novolin R, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
41 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Early Phase 1 Interventional

Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients

NCT02012465
View directory record Official record
Conditions
Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Insulin protocol
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 29, 2026, 5:22 PM EDT
Terminated Phase 4 Interventional Results available

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

NCT03511521
View directory record Official record
Conditions
Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Interventions
NPH Insulin, glargine, Insulin Aspart
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

NCT01768559
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID, Insulin Glargine (Mandatory background drug), Metformin (Background drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
46
States / cities
Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)

NCT02124759
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Sevelamer, Synbiotic, Maltodextrin, High Fat diet, Low Fat diet
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Results available

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

NCT02432716
View directory record Official record
Conditions
Down Syndrome
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Sep 29, 2026, 5:22 PM EDT
Recruiting Phase 1 Interventional

Topical Insulin for Glaucoma

NCT05206877
View directory record Official record
Conditions
Glaucoma
Interventions
Insulin, 4 units, Insulin, 20 units, insulin, 4 units twice daily, insulin, 20 units twice daily, insulin, 4 units three times daily, insulin, 20 units three times daily
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 29, 2026, 5:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Insulin and Insulin Pulses During Fasting

NCT06424015
View directory record Official record
Conditions
PreDiabetes
Interventions
Intralipid and heparin, Saline
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN

NCT00672854
View directory record Official record
Conditions
Parenteral Nutrition
Interventions
ClinOleic 20% Intravenous Emulsion, Intralipid, 20% Intravenous Emulsion
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sympathetic Activation in Obesity

NCT04946552
View directory record Official record
Conditions
Obesity, Healthy
Interventions
PET Scan, Mixed Meal Test, Muscle sympathetic nerve activity (MSNA), Oral Glucose Tolerance Test, Body Composition, Percent Body Fat & Percent Body Water (Tanita scale), CT Scan, Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)
Diagnostic Test · Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 29, 2026, 5:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Plasma Insulin Levels

NCT06597149
View directory record Official record
Conditions
Healthy
Interventions
Transcutaneous Auricular Vagus Nerve Stimulation
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.

NCT01436045
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
65 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

NCT04585776
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
LY900014, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • West Des Moines, Iowa • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients

NCT00645827
View directory record Official record
Conditions
Glucose, Blood
Interventions
IICE Dosing, Healthcare Provider dosing
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2014 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital

NCT01203774
View directory record Official record
Conditions
Diabetes
Interventions
Glargine insulin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

NCT01654380
View directory record Official record
Conditions
Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions
LY2605541, Insulin glargine
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

NCT00705536
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 29, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients

NCT01792830
View directory record Official record
Conditions
Poor Glycemic Control
Interventions
Metformin, Glargine insulin, Glulisine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Sep 29, 2026, 5:22 PM EDT